GlassScriptPhysician profile
Stacy L Corum
NPI 1609275502
$3,644.91
in general payments reported to CMS, 2019-2025
29 companies · $901 in 2025
The $901 reported for 2025 was more than what 95% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $812 · 2022: $782 · 2023: $637 · 2024: $514 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.09 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $600.15 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $528.02 | 2021-2025 | |
| Biogen, INC. | $501.50 | 2024-2025 | Zurzuvae |
| Daiichi Sankyo INC. | $205.38 | 2021-2022 | |
| Aspira Women'S Health INC | $195.91 | 2022 | |
| Astellas Pharma US INC | $177.42 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $165.10 | 2021-2025 | Paragard T 380a |
| Organon LLC | $154.81 | 2022-2025 | Nexplanon |
| Exeltis, USA INC. | $154.43 | 2021-2025 | Slynd |
| Novo Nordisk INC | $126.52 | 2023 | Wegovy |
| Shield Therapeutics INC | $106.85 | 2023-2025 | Accrufer |
| Hologic Sales and Service, LLC | $106.42 | 2021-2025 | Thinprep 2000 Processor, Aptima, Third Wave |
| Evofem Biosciences, INC. | $89.85 | 2021-2022 | |
| Millicent US INC | $82.55 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Baxter Healthcare | $63.07 | 2023-2025 | Perclot |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $58.58 | 2023-2024 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $52.49 | 2021-2024 | |
| Agile Therapeutics, INC. | $47.42 | 2021-2023 | Twirla |
| Mylan Pharmaceuticals INC. | $36.31 | 2021 | |
| Scynexis, INC. | $32.10 | 2022 | |
| Pharmacosmos Therapeutics INC. | $29.21 | 2024-2025 | Monoferric |
| Avion Pharmaceuticals | $27.41 | 2021 | |
| Lilly USA, LLC | $19.19 | 2025 | Zepbound |
| Olympus America INC. | $15.56 | 2023 | Endoeye Flex Deflectable Videoscope |
| Pfizer INC. | $14.59 | 2023 | |
| Merck Sharp & Dohme LLC | $14.44 | 2024 | Gardasil, Gardasil 9 |
| Therapeuticsmd, INC. | $14.32 | 2021 | |
| Sanofi Pasteur INC. | $13.93 | 2025 | |
| Currax Pharmaceuticals LLC | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Corum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.